Giorgio Milazzo

Bologna, 40126, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 31 publications

The cell-permeable iron chelator M606 inhibits MYCN-driven neuroblastoma via an E2F3-mediated response.

The cell-permeable iron chelator M606 inhibits MYCN-driven neuroblastoma via an E2F3-mediated response.

Journal: Proceedings of the National Academy of Sciences of the United States of America

Published: June 02, 2025

Non-canonical activating roles of RCoR2 sustain transcription in adrenergic neuroblastoma.

Non-canonical activating roles of RCoR2 sustain transcription in adrenergic neuroblastoma.

Journal: Cell reports

Published: December 16, 2024

Systematic Targeting of GD2-Positive Neuroblastoma Tumors With a Photooncolytic Phage Nanovector Platform.

Systematic Targeting of GD2-Positive Neuroblastoma Tumors With a Photooncolytic Phage Nanovector Platform.

Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)

Published: November 20, 2024

The transcriptional co-repressor Runx1t1 is essential for MYCN-driven neuroblastoma tumorigenesis.

The transcriptional co-repressor Runx1t1 is essential for MYCN-driven neuroblastoma tumorigenesis.

Journal: Nature communications

Published: April 05, 2023

MYCN Amplification, along with Wild-Type RB1 Expression, Enhances CDK4/6 Inhibitors' Efficacy in Neuroblastoma Cells.

MYCN Amplification, along with Wild-Type RB1 Expression, Enhances CDK4/6 Inhibitors' Efficacy in Neuroblastoma Cells.

Journal: International journal of molecular sciences

Published: December 22, 2022

Single-Cell Sequencing Identifies Master Regulators Affected by Panobinostat in Neuroblastoma Cells.

Single-Cell Sequencing Identifies Master Regulators Affected by Panobinostat in Neuroblastoma Cells.

Journal: Genes

Published: October 11, 2022

Contribution of CACNA1H Variants in Autism Spectrum Disorder Susceptibility.

Contribution of CACNA1H Variants in Autism Spectrum Disorder Susceptibility.

Journal: Frontiers in psychiatry

Published: January 19, 2022

Targeting Oncogenic Transcriptional Networks in Neuroblastoma: From N-Myc to Epigenetic Drugs.

Targeting Oncogenic Transcriptional Networks in Neuroblastoma: From N-Myc to Epigenetic Drugs.

Journal: International journal of molecular sciences

Published: November 05, 2021

MYCN-driven fatty acid uptake is a metabolic vulnerability in neuroblastoma.

MYCN-driven fatty acid uptake is a metabolic vulnerability in neuroblastoma.

Journal: Nature communications

Published: August 24, 2021

A G316A Polymorphism in the Ornithine Decarboxylase Gene Promoter Modulates MYCN-Driven Childhood Neuroblastoma.

A G316A Polymorphism in the Ornithine Decarboxylase Gene Promoter Modulates MYCN-Driven Childhood Neuroblastoma.

Journal: Cancers

Published: March 07, 2021

CHAF1A Blocks Neuronal Differentiation and Promotes Neuroblastoma Oncogenesis via Metabolic Reprogramming.

CHAF1A Blocks Neuronal Differentiation and Promotes Neuroblastoma Oncogenesis via Metabolic Reprogramming.

Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)

Published: January 04, 2021

Corrigendum to: "MAX to MYCN intracellular ratio drives the aggressive phenotype and clinical outcome of high risk neuroblastoma" [Biochim. Biophys. Acta, Gene Regul. Mech. 1861 (2018) 235-245].

Corrigendum to: "MAX to MYCN intracellular ratio drives the aggressive phenotype and clinical outcome of high risk neuroblastoma" [Biochim. Biophys. Acta, Gene Regul. Mech. 1861 (2018) 235-245].

Journal: Biochimica et biophysica acta. Gene regulatory mechanisms

Published: November 03, 2020

Showing 1-12 of 31

Last Updated: 09/26/2026